



PRESS RELEASE

Restructuring plan for THERAMetrics holding AG

Capua, 8 October 2015 – **Pierrel S.p.A.** (“**Pierrel**” or the “**Company**”) announces that today THERAMetrics holding AG (“**THERAMetrics**”), a Swiss company in which Pierrel holds an investment of some 27% in the share capital and whose shares are listed on the SIX Swiss Exchange, has disclosed that on 7 October 2015 its Board of Directors approved, in view of the persistent financial difficulties, a new restructuring plan that, as reported in the press release of THERAMetrics, in order to reduce costs further and find financial resources, provides in brief (a) a major reduction in its workforce, (b) the consolidation of decentralised functions, and (c) the sale of certain assets.

In addition, in order to obtain in a short timeframe the necessary financial resources to ensure the continuity of the business, THERAMetrics announced that it has initiated discussions with several potential investors, including its own major shareholders, in order to verify their willingness to assume, in a short timeframe, a commitment to invest additional resources in the capital of the company. The Company clarifies that it has received, as of today, no request for financial support by THERAMetrics and that any assessment in this regard will be made by Pierrel if such a request were to be made by the Swiss company, also after consideration of the terms and conditions of the potential investment.

For further information please refer to the press release published today by THERAMetrics holding AG on the web site www.therametrics.com.

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years’ experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“**DRR2.0**”) and Integrated Clinical Development Services (“**ICDS**”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Raffaele Petrone

Global Consult S.r.l.

Media Relations

Rossana Del Forno



e-mail:

investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

e-mail:

areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665